Lupride Injection contains Leuprolide acetate, a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) used primarily in the management of hormone-responsive conditions. Each 0.5 ml ampoule delivers 1 mg of Leuprolide, which acts by initially stimulating and subsequently downregulating pituitary GnRH receptors, leading to decreased secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This results in reduced production of gonadal steroids such as testosterone and estrogen, making Lupride Injection effective in treating hormone-dependent diseases including prostate cancer, endometriosis, uterine fibroids, and precocious puberty. The drug is administered via intramuscular or subcutaneous injection, with dosing schedules tailored to the specific indication and patient response. Lupride Injection is contraindicated in pregnancy and hypersensitivity to Leuprolide or any formulation components. Common adverse effects include hot flashes, injection site reactions, headache, and mood changes, while long-term use may lead to decreased bone mineral density. Careful monitoring of hormone levels and clinical response is recommended during therapy. Lupride Injection should be prescribed and administered under the supervision of a qualified healthcare professional experienced in managing hormone-related disorders.